Expression of the multidrug resistance proteins P-glycoprotein, encoded by the MDR1 gene, multidrug resistanceassociated protein (MRP1) and the lung resistance-related protein or major vault protein (LRP/MVP) is associated with clinical resistance to chemotherapy in acute myeloid leukemia (AML). Recently, the breast cancer-resistant protein (BCRP), the equivalent of mitoxantrone-resistant protein (MXR) or placental ABC transporter (ABCP), was described in AML. We investigated MDR1, MRP1, LRP/MVP and BCRP mRNA expression simultaneously in 20 paired clinical AML samples from diagnosis and relapse or refractory disease, using quantitative Taqman analysis. In addition, standard assays for P-glycoprotein expression and function were performed. BCRP was the only resistance protein that was expressed at a significantly higher RNA level (median 1.7-fold, P = 0.04) at relapsed/refractory state as compared to diagnosis. In contrast, LRP/MVP mRNA expression decreased as disease evolved (P = 0.02), whereas MDR1 and MRP1 mRNA levels were not different at relapse as compared to diagnosis. Also, at the protein level no difference of MDR1 between diagnosis and relapse was found. A significant co-expression of BCRP and MDR1 was found at diagnosis (r = 0.47, P = 0.04). The present results suggest that BCRP, but not MDR1, MRP1 or LRP/MVP is associated with clinical resistant disease in AML.
Introduction
Clinical resistance to chemotherapy in AML is often associated with expression of (membrane) transport-associated multidrug resistance proteins. 1 Expression of P-glycoprotein (P-gp), encoded by the MDR1 gene is an independent adverse prognostic factor for response and survival in de novo acute myeloid leukemia (AML). [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] More recently, it was observed that not only P-gp, but also the multidrug-resistant-associated protein (MRP1) and the lung resistance-related protein (LRP), also designated as the major vault protein (MVP), are expressed in AML. The precise prognostic significance of these latter resistance proteins is not yet known. 8, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Recently, a new drug-resistant protein, ie the breast cancer resistance protein (BCRP), [21] [22] [23] which is the equivalent of the mitoxantrone-resistant protein 24, 25 and of the placental ABC transporter (ABCP), 26 was found to be expressed in AML. 27, 28 BCRP maps to the human chromosome 4q22, between the markers D4S2462 and D4S1557. 26, 29 Little is known about the expression of MDR1, LRP/MVP and MRP1 at presentation and at relapse in the same patients. Paired studies of the expression of these genes in clinical AML samples are limited to small numbers of patients. [30] [31] [32] [33] Consequently, it is still not clear if the expression of these resistance proteins increases from diagnosis to relapse, nor whether a resistant clone which is already present at diagnosis, regrows at relapse. At present, there is no information about the clinical relevance of BCRP gene expression in AML.
We investigated whether MDR1, MRP1, LRP/MVP and BCRP mRNA expression evolves from diagnosis to relapse/refractory disease in 20 paired AML samples, using a quantitative real-time PCR assay. As upregulation of MDR1 has been claimed as a major event in resistant AML, we also investigated P-glycoprotein in these cells.
Patients
Bone marrow samples of 20 acute myeloid leukemia (AML) patients (4 children, aged Ͻ16 years and 16 adults), median age 38 years (range 1-66 years), were obtained from the iliac crest both at diagnosis and at time of first relapse (n = 18) or primary refractory disease (n = 2) ( Table 1 ). The bone marrow samples were collected between August 1988 and October 1997. AML classification, performed according to the FrenchAmerican-British (FAB) criteria 34 was M1 (n = 6), M2 (n = 8), M4 (n = 1), M5 (n = 3), M6 (n = 2). Cytogenetic analysis was carried out by standard techniques, and the findings were described according to the international nomenclature. 35 All patients and/or their parents had given informed consent, and they were treated according to the Helsinki agreement. Most of them were included in treatment protocols of the DutchBelgian Hemato-Oncology Collaborative Group (HOVON 4 resp. HOVON 29) for young adults, European Organisation for Research and Treatment of Cancer (EORTC LAM 9/11) for elderly patients, and the Dutch Childhood Leukemia Study Group (DCLSG: ANLL 82, 87 and 94) for the children. 30, 36, 37 At relapse or in the case of refractory disease after repopulation following induction therapy, adult patients were treated according to the HOVON 30 relapse protocol. Treatment of the four pediatric patients was by the institutional protocol ( Table 1) . As shown in Table 1 , for some adult patients individual treatment choices were made. One patient died before reinduction treatment started because of septicemia. The induction therapy used in HOVON 4, 29 and 30, the EORTC 9/11 and the DCLSG ANLL protocols all consisted of an anthracycline and Ara-C. 30 Complete remission status was defined as normocellular marrow, with Ͻ5% blasts in a BM smear, with normal peripheral blood counts. ) ; Neutral, normal and other karyotypes. Ara-C, cytosine-arabinoside; Ara-C*, high-dose Ara-C; Ara-C**, moderate-dose Ara-C; DNR, daunorubicin; Adria, adriamycin; Ida, idarubicin; VP16, etoposide.
Materials and methods

Patient samples
Bone marrow aspirates were obtained in heparinized tubes. Mononuclear bone marrow cells (MNC) were collected by Ficoll-Hypaque density gradient centrifugation (density 1.077 g/m 3 ) (Pharmacia, Uppsala, Sweden). To obtain purified samples with more than 85% of blasts, T cell depletion and adherence depletion was performed as described. 38 Cells were cryopreserved in Iscove's Dulbecco's medium (IMDM; Gibco, Paisley, UK) supplemented with 10% dimethyl sulfoxide (DMSO; Merck, Darmstadt, Germany) and 20% fetal calf serum (FCS; Gibco) and stored in liquid nitrogen. On the day of the experiments bone marrow cells were thawed. For flow cytometry experiments, cells were washed and resuspended in IMDM supplemented with 10% FCS and gentamycin at a concentration of 4 × 10 6 cells per ml. Before RNA and DNA isolation cells were washed with PBS (Gibco).
LRP/MVP, MRP1, MDR1 and BCRP mRNA analysis Isolation of RNA:
Total RNA was isolated using the TRI-SOLV extraction as described by the manufacturer (Biotecx, Houston, TX, USA). RNA was aliquoted and stored at −80°C. RNA samples were analyzed for RNA integrity by gel electrophoresis.
cDNA synthesis:
cDNA was synthesized by the use of the TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, USA). cDNA was diluted, aliquoted and stored at −80°C.
Quantitative real-time PCR:
The mRNA levels of MDR1, MRP1, LRP/MVP, BCRP and two endogenous reference genes, ie glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and porphobilinogen deaminase (PBGD), were measured by quantitative real-time PCR based upon Taqman chemistry on an ABI PRISM 7700 sequence detector (Applied Biosystems).
PCR products were detected using a dual-fluorescent nonextendable probe containing a FAM reporter and TAMRA quencher for all reactions except for the GAPDH reaction in which FAM was replaced by VIC. All primers and probes, designed by the oligo 6.0 primer analysis software (Medprobe, Oslo, Norway), did not amplify contaminating genomic DNA ( Table 2 ). The GAPDH mRNA levels were measured using the Pre-developed TaqMan Assay Reagents for human GAPDH (Applied Biosystems). Forty nanograms of patient sample cDNA were used as a template in duplicate in the presence of 300 nM forward and reverse primers, 200 nM of probe, 200 M dNTPs, 1.25 U of AmpliTaq DNA polymerase and 4 mM MgCl 2 in sample buffer A (Applied Biosystems) in a total volume of 50 l. Samples were heated for 10 min at 95°C and amplified for 50 cycles of 15 s at 95°C and 60 s at 60°C. As a positive control, a serial dilution of cDNA from a cell line RNA pool (CEM, K562 and two EBV-induced lymphoblastoid B cell lines) in H 2 O was used. All PCR reactions were performed with comparable efficiencies that exceeded E = 0.95. The relative expression levels of MDR1, MRP1, LRP/MVP and BCRP1 mRNA were calculated using the comparative C t method (K Livak, User bulletin No. 2). 39 Briefly, the target PCR C t values, ie the cycle number at which emitted fluorescence exceeds the 10 times standard deviation of base-line emissions as measured between cycles 3 and 15, is normalized to the average C t -value of the reference PCRs (GAPDH and PBGD). From this ⌬C t -value, the relative expression level for each target PCR was calculated using the equation: relative expression = 2
. The average C t value of two reference PCRs was used instead of a single reference reaction to limit patient samplespecific variation in housekeeping gene expression. All RT-PCR analyses were performed twice on different days and in duplicate with similar if not identical results.
P-glycoprotein expression and function
Expression of P-glycoprotein:
To measure the expression of P-gp, cells were incubated at room temperature using the monoclonal anti-P-gp antibodies (Moabs) MRK16 40 (Kamiya Biomedical Company, Tukwila, WA, USA) at a concentration of 10 g/ml and also, in separate tubes, using Moab UIC2 41 (Immunotech, Marseille, France) at a concentration of 12.5 g/ml or with an isotype matched mIgG2a control antibody (Sigma, St Louis, MO, USA) at a concentration of 10 g/ml. Cell-bound antibodies were detected by fluorescein isothiocyanate (FITC)-labeled rabbit anti-mouse immunoglobulin antibodies (DAKO, Glostrup, Denmark). Results are given as the ratio of the mean fluorescence of cells incubated with the anti-P-gp antibody divided by the mean fluorescence of cells incubated with the control mIgG2a antibody. To measure the expression of P-gp in CD34-positive (CD34-PECy5) cells, cells were labeled with phycoerythrin-Cy5-labeled CD34 antibody or as a control phycoerythrin-Cy5-labeled mIgG1 antibody (Immunotech).
Function of P-glycoprotein:
For measurement of the function of P-gp, the fluorescent molecule rhodamine123 (Rho123) (Sigma) was used as a P-gp substrate. 42, 43 Cells were incubated for 1 h at 37°C at 5% CO 2 in the absence or presence of 2 M of the P-gp modulator PSC SDZ 833 (Novartis, Basel, Switserland). Next, 200 ng/ml Rho123 was added to the cells. A sample was taken at t = 0 min to correct for background fluorescence and at t = 75 min to measure intracellular Rho123 accumulation. Results were calculated as the PSC/Rho123 accumulation ratio of the mean intracellular Rho 123 fluorescence of cells exposed to PSC 833 divided by the mean intracellular Rho123 fluorescence of cells not exposed to PSC 833.
As controls in each experiment, the drug-sensitive human Leukemia myeloma cell line 8226 S and the drug-resistant P-gp expressing variant 8226 D6 cells 44 were included. Taking all experiments together, the mean ratio of P-gp function of the negative control cell line 8226 S was 0.91 ± 0.07 (mean ± s.d.). The mean ratio of P-gp function of the positive control cell line 8226 D6 was 7.03 ± 4.69 (mean ± s.d.).
For analysis of the function of P-gp in CD34-positive cells, cells were labeled with the PE-erythrin-Cy5-labeled CD34 Moab or with mIgG1 PE-Cy5 (isotype matched control antibody (Immunotech). Fluorescence was measured using a FACScalibur flow cytometer (Becton Dickinson, San José, CA, USA).
Cells were incubated with 0.1 M TO-PRO-3 (Molecular Probes, Eugene, OR, USA) to exclude non-viable cells in both the functional and expression studies.
Statistical analysis
The mRNA expression levels of the resistance proteins and of P-glycoprotein levels at time of relapse or refractory disease as compared to the levels at diagnosis were calculated using the univariate Wilcoxon matched-pairs signed-ranks test, which was thus restricted to patients with data available both at diagnosis and at relapse and/or refractory disease state. Also, MRP1, LRP/MVP, BCRP and MDR1 mRNA levels were compared with each other as well with patient characteristics at diagnosis and at relapse and/or refractory disease, by calculation of the Spearman rank correlation in order to test whether the two variables concerned are independent. All Pvalues are two-sided and a significance level of ␣ = 0.05 was used.
Results
AML samples of 20 patients were investigated both at diagnosis and at relapse (n = 18) or refractory disease (n = 2). The patient characteristics are listed in Table 1 . BCRP was the only resistance protein that was expressed at a significantly higher mRNA level at relapse or refractory disease state than at diagnosis ( Figure 1, Table 3 ). No differences between the levels of MDR1 mRNA and MRP1 mRNA were observed at relapse compared with diagnosis, whereas LRP/MVP mRNA even decreased significantly at relapse (Table 3) . BCRP mRNA expression was not associated with FAB classification, nor with CD34 expression or cytogenetic abnormalities at diagnosis. Interestingly, at presentation lower peripheral white blood cell counts (WBC) were associated with higher BCRP mRNA levels (r = −0.67, P = 0.001).
At diagnosis, a correlation between the expression of BCRP mRNA and MDR1 mRNA expression was found (r = 0.47, P = 0.04). None of the other analyzed resistance proteins correlated with each other. Upregulation of BCRP mRNA at the time of relapse (Table 3) was not associated with upregulation of transcription of any of the other resistance genes. At relapse, only co-expression of MRP1 mRNA and LRP/MVP mRNA was found (r = 0.49, P = 0.03).
We observed that BCRP mRNA expression was correlated with a positive effect of PSC 833 on Rho 123 retention in diagnostic samples, but not in relapsed/refractory AML samples (Table 4) . This functional assay also showed a strong correlation between P-glycoprotein function and MDR1 mRNA levels at diagnosis (r = 0.59, P = 0.01) and at relapse (r = 0.88, P = 0.04). The MDR1 mRNA levels correlated well
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Figure 1
BCRP, MDR1, MRP1, LRP/MVP mRNA expression in paired AML samples at diagnosis. The P value indicates the difference between the two time points in a paired analysis. 20 20 The P values indicate the differences between diagnosis and relapse or refractory disease using the Wilcoxon signed-ranks test. 'n' indicates the number of patients involved in the paired analysis. The P value indicates the difference between diagnosis and relapse/refractory disease; *indicates a statistically significant difference between relapse and diagnosis. (r), the Spearman rank-correlation coefficient; *correlation is significant at the 0.05 level; **correlation is significant at the 0.01 level.
with the expression of P-glycoprotein (r = 0.57, P = 0.009 for MRK16 and r = 0.52, P = 0.02 for UIC2) at relapse, but not at diagnosis (r = 0.15, P = 0.55, respectively (r = 0.47, P = 0.06).
Discussion
Clinical resistance to chemotherapy is a major problem in the treatment of AML. It is conceivable that functional expression of the resistance proteins P-gp, MRP1, LRP/MVP or BCRP is associated with the development of relapse and/or refractory disease. For instance, MDR1 and MRP1 have been reported as adverse prognostic factors for CR and survival 1, 5, 7, 8, 10, 17, 20 Although we should state that only 20 patients were investigated, so far this is the first report of a cohesive analysis of the expression of these resistance proteins, and the largest paired analysis of clinical samples of AML patients using quantitative PCR. Our data demonstrate that BCRP is the single resistance gene which is expressed at a higher level at relapse as compared to diagnosis (P = 0.04). In contrast to what has been suggested in the literature, no increase of MRP1 or MDR1 levels was found at relapse. LRP/MVP mRNA levels even showed a decrease at the time of relapse/refractory disease. Increased levels of BCRP mRNA were not correlated with an increase of expression of any of the other resistance genes at time of relapse/refractory disease, leaving only BCRP expression as a possible contributor to refractory/relapsed disease. BCRP, also identified as mitoxantrone resistance protein (MXR) or ABCP (ABC transporter cloned from human placenta) is responsible for drug resistance phenotypes in MCF7 cell lines after transfection experiments. Resistance was found for mitoxantrone, daunomycin, doxorubicin and DNA topoisomerase I inhibitors like topothecan and SN-38, the active form of irinothecan, while sensitivity to platinum, paclitaxel and vincristine was retained. 22, 28, 45, 46 The BCRP/MXR/ABCP gene is evolutionary distinct from the other members of the ABC transporter family that encode P-gp and MRP1, being on a completely separate limb of the phylogenetic tree. 28 In contrast to the MDR1 and MRP1 genes, it encodes a protein which is a half-transporter molecule requiring homo-or hetrodimerization in order to function. This suggests a unique and probably complementary role for BCRP among the other resistance proteins. 28, 47, 48 In normal tissues, BCRP is quite distinctly expressed from P-gp and MRP1. BCRP mRNA is highest in the placenta 22, 26 and certain areas of the midbrain (putamen), and relatively low in other normal fetal and adult tissues. 28 Until now, no data were available about the role of BCRP in clinical resistance in AML. One study in clinical samples of AML patients by Ross et al, 27 reported a 1295-fold variation in expression levels in the AML patients tested at diagnosis. They also described a weak association (r = 0.44) of MDR1 and BCRP mRNA expression in nine AML patients in whom both drug resistance proteins were investigated. Based on this limited analysis, it was suggested that this co-expression of BCRP and MDR1 may explain the disappointing results of MDR1 reversal agents in clinical studies in AML. Interestingly, Leith et al 49 described, in a large South West Oncology Group (SWOG) study, a distinct subgroup of AML patients in whom the blast cells exhibited cyclosporin-resistant efflux of Rho 123, that was not correlated with MDR1, MRP1 or LRP/MVP protein expression. They suggested the existence of another as yet undefined efflux mechanism in adult AML blasts cells.
In our group of AML patients the BCRP mRNA levels varied 240-fold at diagnosis. At diagnosis, we also found a weak, but significant correlation between the expression of BCRP and MDR1 mRNA (r = 0.47, P = 0.04), and not between any of the other resistance proteins. This association was confirmed by a correlation between BCRP mRNA expression and functional drug efflux which could be inhibited by PSC833. This correlation disappeared at relapse, where no co-expression of BCRP and MDR1 was observed, leaving only BCRP expression as a possible contributor to refractory disease. If co-expression of BCRP and MDR1 did occur in AML, this could create the possibility for new clinical trials using reversal agents that block both P-gp and BCRP such as GF120918. 25, 50, 51 Moreover, recent studies have identified additional BCRP-specific modulators such as fumitremorgin C Leukemia (FTC) and analogues 46, 51 which may be candidates for feasibility studies of BCRP blockers in a clinical setting.
Our study is the first that has investigated BCRP mRNA expression, simultaneously with MDR1, MRP1 and LRP/MVP mRNA expression in paired AML samples and shows that BCRP is the only drug resistance gene which is expressed at a higher level at relapse/refractory disease. Previous studies have shown conflicting results with regards to MDR1, MRP and LRP/MVP upregulation at relapse, probably because they were often performed in a heterogeneous pool of diagnostic, relapse and secondary AML samples (Table 5) . 12, 16, 29, [52] [53] [54] [55] [56] [57] [58] It has often been suggested that MDR1 expression at the time of relapse is higher as compared to diagnosis. 33, [59] [60] [61] [62] [63] [64] [65] In the present study, we did not find a higher level of MDR1 mRNA, nor P-glycoprotein function and expression at relapse or in refractory disease in these AML patients.
We conclude that BCRP and not MDR1, LRP/MVP or MRP1 may play a relevant role in the development of relapsed or refractory AML. Studies in larger cohorts of AML patients are necessary to establish the prognostic role of expression and co-expression of these drug resistance proteins in relation to other already appreciated clinical prognostic factors.
